[{"id":"85b0714e-dfbe-462f-9e1b-b16f61823ed6","acronym":"EPIcol","url":"https://clinicaltrials.gov/study/NCT06147960","created_at":"2023-11-28T20:16:44.810Z","updated_at":"2024-07-02T16:35:27.930Z","phase":"","brief_title":"Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer","source_id_and_acronym":"NCT06147960 - EPIcol","lead_sponsor":"Centre Hospitalier Universitaire de Nīmes","biomarkers":" BIRC3 • XIAP","pipe":"","alterations":" ","tags":["BIRC3 • XIAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-11-28"},{"id":"33519654-a406-4cd2-9505-88653cfb3f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00372736","created_at":"2021-01-22T18:52:09.360Z","updated_at":"2024-07-02T16:35:40.958Z","phase":"Phase 1","brief_title":"AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors","source_id_and_acronym":"NCT00372736","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" XIAP","pipe":"","alterations":" ","tags":["XIAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • GEM 640"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 07/27/2006","start_date":" 07/27/2006","primary_txt":" Primary completion: 03/24/2009","primary_completion_date":" 03/24/2009","study_txt":" Completion: 01/06/2012","study_completion_date":" 01/06/2012","last_update_posted":"2023-08-04"},{"id":"b6de17b5-794f-440f-a5e5-f1a349e84075","acronym":"RUE-DDGP","url":"https://clinicaltrials.gov/study/NCT04999878","created_at":"2021-08-11T14:55:25.152Z","updated_at":"2024-07-02T16:36:26.648Z","phase":"Phase 4","brief_title":"A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.","source_id_and_acronym":"NCT04999878 - RUE-DDGP","lead_sponsor":"Zhengzhou University","biomarkers":" IL2 • CD27 • XIAP • PRF1 • UNC13D • ISG20 • RAB27A • STXBP2","pipe":"","alterations":" ","tags":["IL2 • CD27 • XIAP • PRF1 • UNC13D • ISG20 • RAB27A • STXBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Jakafi (ruxolitinib) • etoposide IV • dexamethasone • Oncaspar liquid (pegaspargase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/30/2021","start_date":" 05/30/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2021-08-11"}]